

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden

hours per response: 0.5

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>PRASAD SUYASH</u> (Last) (First) (Middle) <u>C/O AUDENTES THERAPEUTICS, INC.</u> <u>600 CALIFORNIA STREET, 17TH FLOOR</u> (Street) <u>SAN FRANCISCO</u> <u>CA</u> <u>94108</u> (City) (State) (Zip)		2. Issuer Name and Ticker or Trading Symbol <u>Audentes Therapeutics, Inc. [BOLD]</u> 3. Date of Earliest Transaction (Month/Day/Year) <u>12/01/2017</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Senior VP & Chief Med Officer</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	--	---

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/01/2017		M ⁽¹⁾		6,770	A	\$0.79	6,770	D	
Common Stock	12/01/2017		S ⁽¹⁾		6,770	D	\$28.451 ⁽²⁾	0	D	
Common Stock	12/01/2017		M ⁽¹⁾		1,230	A	\$0.79	1,230	D	
Common Stock	12/01/2017		S ⁽¹⁾		1,230	D	\$28.9842 ⁽³⁾	0	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date					
Stock Option (right to buy)	\$0.79	12/01/2017		M ⁽¹⁾	8,000	(4)	02/18/2024	Common Stock 8,000	\$0.00	80,870	D	

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was \$27.93 and the highest price at which shares were sold was \$28.91. The reporting person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.

3. Represents the weighted average sale price. The lowest price at which shares were sold was \$28.95 and the highest price at which shares were sold was \$29.04.

4. The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.

Remarks:

/s/ Thomas Soloway as
attorney-in-fact for Suyash 12/05/2017
Prasad

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

**** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).**

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.